Skip to content

Trial Summary

A phase III, randomised, opem-label, multi-center, global study to determine the efficacy and safety of durvalumab alone for adjuvant treatment in patients with muscle-invasive bladder cancer

Acronym:

NIAGARA

ACTRN/NCT /ethics:

NCT03732677

Scientific title:

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

Sponsor / Cooperative group:

AstraZeneca

Trial & Patient Characteristics

Cancer TypeBladder
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream muscle-invasive bladder cancer
Cancer StageAll stages
Anticipated Start Date2018-11-16
Anticipated End Date2025-12-18

Participating Hospitals

HospitaltLyell McEwin Hospital
Clinical Trial CoordinatorAndy Phay
Emailandy.phay@sa.gov.au
Phone08 8282 0833
Principal InvestigatorDr Christopher Hocking
Recruitment StatusRecruiting